To facilitate the clinical adoption of new technologies that will create value for patients, Nanyang Technological University, Singapore (NTU Singapore), Agency for Science, Technology and Research (A*STAR), and National Healthcare Group (NHG) have launched co11ab Novena (co11ab), an incubator to support biomedical technology (BioMedtech) startups make the leap from research and development into commercialisation of their innovations.

co11ab is the first such outfit to be embedded in Health City Novena, an integrated community of healthcare, medical education, and translational research.

Located in NTU Singapore’s Lee Kong Chian School of Medicine (LKCMedicine), the S$15 million incubator aims to be a national innovation and translational hub that brings together research, clinical, and venture creation activities, creating an environment that spurs knowledge sharing, innovation, and collaboration. co11ab is expected to be fully operational in the first quarter of 2023.

It will drive new BioMedtech startups by providing entrepreneurs access to industry expertise, mentorship, and funding support to develop their ideas and concepts into products. The startups will also be guided to implement viable growth strategies to expand overseas.

By being located in the heart of the Novena healthcare district, start-ups incubated by co11ab can potentially tap on the expertise of NTU LKCMedicine scientists and NHG clinicians, who specialise in the following key research areas: • Skin and chronic wounds • Ageing/Rehabilitation • Mental Health • Infectious Diseases • Metabolic Health/Vascular Diseases • Regenerative Medicine